hydroxylase


Also found in: Medical, Encyclopedia, Wikipedia.

hydroxylase

(haɪˈdrɒksɪˌleɪz)
n
(Biochemistry) an enzyme useful in hydroxylation
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014
References in periodicals archive ?
Vadadustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, or HIF-PHI, in global Phase 3 development for the treatment of anemia due to CKD in dialysis dependent, or DD,-CKD patients and non-dialysis dependent, or NDD,-CKD patients.
United Kingdom-based GlaxoSmithKline has submitted a Japanese New Drug Application (JNDA) to the Ministry of Health, Labour and Welfare, seeking marketing approval for Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, it was reported yesterday.
Release date- 21082019 - GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the submission of a Japanese New Drug Application (JNDA) to the Ministry of Health, Labour and Welfare seeking marketing approval for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of patients with renal anaemia due to chronic kidney disease (CKD).
Daprodustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor, a new class of drugs which encourage the bone marrow to increase red blood cell production.
Novel and prevalent CYP11B1 gene mutations in Turkish patients with 11-[beta] hydroxylase deficiency.
Nonstandard abbreviations: StAR, steroidogenic acute regulatory protein; CYP11A1, P450 side-chain cleavage enzyme; CYP11B1, 11[beta] hydroxylase; CYP11B2, aldosterone synthase; CYP17A1, 17 [alpha]-hydroxylase/ 17,20-lyase; CYP21A2,21-hydroxylase; HSD3B2, 3[beta]-hydroxysteroid dehydrogenase type 2; HSD11B1, 11[beta]-hydroxysteroid dehydrogenase type 1; HSD11B2, 11[beta]-hydroxysteroid dehydrogenase type 2; HSD17B, 17 [beta]-hydroxysteroid dehydrogenase; SRD5A2, 5[alpha]-reductase type 2; CYP19A1, P450 Aromatase; SULT2A1, sulfotransferase 2A1.
HLADR5 and C4BQO high frequency and antinuclear antibodies positivity in patients with 21 hydroxylase deficiency from Campania region.
Background: Phenylalanine hydroxylase (PAH) gene is the well-known causative gene for classic Phenylketonuria (PKU) (OMIM#261600) disease, with more than 500 reported mutations.
Genetic 21 hydroxylase deficiency and deletion in CYP21A2 gene in line with salt depletion form were detected in patients for whom hydrocortisone, mineralocorticoid and salt replacement treatment were started.
Extrarenal expression of 1-alpha hydroxylase occurs in alveolar macrophages, the placenta, keratinocytes, prostate cancer, colon cancer, breast cancer, pancreas, brain, adrenal medulla, and vascular endothelial cells.